Effects of Intragastric Balloon on Body Mass Index, Lipid Profile and Blood Glucose Regulation: A Prospective Study

Öz

Objective: Obesity remains an increasing public health and socioeconomic problem. Life style changes including healthy diet and physical activity are the first-line therapy for successful weight loss. The intragastric balloon has been considered as an effective and reversible, non-surgical method for weight loss. In this study, we aimed to investigate the effects of Intragastric balloon on weight loss, lipid profiles and blood glucose regulation in obese patients
Methods: 75 consecutive Intragastric balloon patients (55 Female, 20 Male) with a mean age of 35.2±9.6 years were included in this study. The study was conducted prospectively and an air-filled intragastric balloon was introduced in ambulatory settings. In this study, patients’ pre-intervention body mass index, peripheral blood parameters such as HbA1c, lipid profiles were recorded and compared with post-intervention values.
Results: The median intervention time for intragastric balloon application was 13 min (8-19). After follow-up period of median 186 days (180-211), BMI was reduced significantly, 41.6±6.7 vs. 34.9±6.4 kg/m2 (p<0.001). The median excess weight loss was found to be 33.2% (14-81.1). There is no statistically significant difference between pre-intervention and post-intervention valuables in terms of low-density lipoprotein, high-density lipoprotein, cholesterol and triglycerides levels (p>0.05). On the other hand, only pre and post-intervention HbA1c level was to be statistically significant (p=0.001)
Conclusion: There was significant change in BMI and HbA1c level with the intervention of intragastric balloon after follow-up period. For long-term benefit of balloon, further studies are needed.
Key words: Body mass index, HbA1c, Intragastric balloon, obesity

Anahtar Kelimeler

• -

İntragastrik Balonun Vücut Kitle İndeksi, Lipit Profili ve Kan Şekeri Regülasyonu Üzerine Etkileri: Prospektif Çalışma

Öz

Amaç: Obezite giderek artan bir halk sağlığı ve sosyoekonomik sorun olmaya devam etmektedir. Sağlıklı beslenme ve fiziksel aktivite de dâhil olmak üzere yaşam tarzı değişiklikleri başarılı kilo kaybı için ilk basamak tedavi şekli olarak kabul görülmektedir. Gastrik balon kilo kaybı için etkili, geri dönüşümlü ve cerrahi olmayan bir yöntemdir. Çalışmanın amacı, obez hastalarda intragastrik balonun kilo kaybı, lipit profili ve kan şekeri düzenlenmesine etkilerini araştırmaktır. Yöntemler: Bu çalışmada hastaların 35,2 ± 9,6 yaş ortalaması ile 75 ardışık mide balonu hastası (55 Bayan, 20 Erkek) çalışmaya dâhil edildi. Çalışma prospektif olarak planlandı ve hava-dolu mide balonu kontrolleri ayaktan poliklinikte yapıldı. Bu çalışmada, hastaların uygulama öncesi vücut kitle indeksi, HbA1c ve lipid profilleri gibi periferik kan parametreleri, kaydedilerek müdahale sonrası değerleri ile karşılaştırıldı.Bulgular: Mide balonu uygulaması için medyan müdahale süresi 13 dakika idi. Medyan 186 gün izlem süresinden sonra, BMI, önemli ölçüde 41,6 ± 6,7 ‘den 34,9 ± 6,4‘e azalma tespit edildi (p

Anahtar Kelimeler

• Vücut kitle indeksi, HbA1c, intragastrik balon, obezite

Kaynakça

1. Satman I, Omer B, Tutuncu Y, et al; TURDEP-II Study Group. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013;28:169-180.
2. WHO. Obesity: preventing and managing the global epidemic.
3. Report of a WHO consultation on obesity. Geneva: World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253.
4. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. National Institutes of Health. Obes Res 1998;6:464.
5. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004;12:1197-211.
6. Waseem T, Mogensen KM, Lautz DB, et al. Pathophysiology of obesity: why surgery remains the most effective treatment. Obes Surg 2007;17:1389-1398.
7. Vrabie CD, Cojocaru M, Waller M, et al. The main histopathological
8. gastric lesions in obese patients who underwent sleeve gastrectomy. Dicle Med J 2010;37:97-103.

9. Doldi SB, Micheletto G, Di Prisco F, et al. Intragastric balloon in obese patients. Obes Surg 2000;10:578-581.
10. Buzga M, Evzen M, Pavel K, Tomas K, Vladislava Z, Pavel Z, et al. Effects of the intragastric balloon Medsil® on Weight loss, fat tissue, lipid metabolism, and hormones involved in energy balance. Obes Surg 2014;24:909-915.
11. Genco A, Bruni T, Doldi SB, et al. Bioenterics intragastric Balloon: the Italian experience with 2515 patients. Obes Surg 2005;15:1161-1164.
12. Saruç M, Böler D, Karaarslan M, et al. Intragastric balloon treatment of obesity must be combined with bariatric surgery: a pilot study in Turkey. Turk J Gastroenterol 2010;21:333-337.
13. Kotzampassi K, Grosomanidis V, Papakostas P, et al. 500 intragastric balloons: What happens 5 years thereafter? Obes Surg 2012;22:896-903.
14. Sekino Y, Imajo K, Sakai E, et al. Time-course of changes of visceral fat area, liver volume and liver fat area during intragastric balloon therapy in Japanese super-obese patients. Intern Med 2011;50:2449-2455.
15. Konopko-Zubrzycka M, Baniukiewicz A, Wroblewski E, et al. The effect of intragastric balloon on plasma ghrelin, leptin, and adiponectin levels in patients with morbid obesity. J Clin Endocrinol Metab 2009;94:1644-1649.
16. Crea N, Pata G, Casa DD, et al. Improvement of Metabolic Syndrome following intragastric balloon: 1 year Follow-up Analysis. Obes Surg 2009;19:1084-1088.
17. Forlano R, Ippolito AM, Iacobellis A, et al. Effect of the bioenterics intragastric balloon on weight, insulin resistance and liver steatosis in obese patients. Gastrointest Endosc 2010;71:927-933.
18. Fuller NR, Pearson S, Lau NS, et al. An Intragastric Balloon in the Treatment Of Obese Individuals With Metabolic Syndrome: A Randomized Controlled Study. Obesity (Silver Spring) 2013;21:1561-1570.
19. Yasawy MI, Al-Quorain AA, Hussameddin AM. Obesity and gastric balloon. J Family Community Med 2014;21:196-199.